At the Financial Times’ Global Pharma and Biotech Summit 2024, a panel discussed initiatives aimed at bringing cell and gene therapies to low- and middle-income countries.

The UWWTD will require manufacturers to fund micropollutant removal, but Zentiva says the financial squeeze could mean shortages.

The FDA-approved schizophrenia and bipolar disorder therapy met the primary and secondary endpoint in a Phase III “withdrawal trial”.

At the Financial Times’ Global Pharma and Biotech Summit 2024, a breakout panel discussed how dealmaking remains vital for biopharma companies facing pipeline and revenue pressures.

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor optimism improved following the interest rate cuts by the US Federal Reserve in September 2024.

Sales of the GLP-1RA hit $2.5bn in Q3, a 79% increase over the same period last year.

GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to gauge impact.

Tevogen Bio’s AI effort Tevogen.AI has partnered with Microsoft to advance the development of an HPV specific CTL treatment.

Pioneers like Alnylam Pharmaceuticals have led the RNA interference field for years. Now, a crop of young biotechs is building on that foundation by taking the drugmaking technology in new directions.

Trump has not been vocal about healthcare policies but indicated that RFK Jr. will have a big influence on the sector.

Nxera Pharma has entered a collaboration and licensing agreement with Antiverse to design antibodies for GPCRs.

Ted Sweetser, VP, Ad Partnerships and Strategy, PurpleLab explored the potential implications of the phase-out of cookies for the broader advertising industry.

Industry experts comment on the increasing popularity of compounded medications, particularly GLP-1s, due to drug shortages and the desire for personalized treatments.

The latest news for pharma industry insiders.

GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.

Amgen CEO Robert A. Bradway discusses the potential impact of the election, and politics in general, will have on the industry.

At the Financial Times’ Global Pharma and Biotech Summit 2024, Christophe Weber, president and CEO, Takeda, discusses how trust and collaboration between the biopharma industry and stakeholders can be implemented to support successful healthcare […]

Vertex is approaching two key PDUFA dates in January for new treatments in cystic fibrosis and pain respectively.

The companies’ CAR-T seemed to cause fewer movement disorders in a multiple myeloma trial than J&J’s Carvykti has in other tests, although Wall Street analysts were divided on how the two drugs compare.

Just three years removed from a lucrative IPO, the company will cut jobs for a third time and invest more heavily in cell therapies for diabetes and lupus.